Defining the critical hurdles in cancer immunotherapy
(1, 2)
,
(3)
,
(4, 5, 6)
,
(7)
,
(8, 9)
,
(10)
,
(11)
,
(12)
,
(13)
,
(14)
,
(15)
,
(16, 17)
,
(18)
,
(19, 20)
,
(21, 22)
,
(23)
,
(24)
,
(25)
,
(26)
,
(27)
,
(28)
,
(29)
,
(30)
,
(31, 32)
,
(33)
,
(34)
,
(35)
,
(36)
,
(37)
,
(38)
,
(39)
,
(40, 41)
,
(42)
,
(43)
,
(44, 45)
,
(46)
,
(47)
,
(48)
,
(49)
,
(50)
,
(51)
,
(52)
,
(5)
,
(53)
,
(54)
,
(55)
,
(56)
,
(57)
,
(58)
,
(59)
,
(35)
,
(60)
,
(61)
,
(4, 5, 6)
,
(62)
,
(63)
,
(64)
,
(65)
,
(66)
,
(67)
,
(68)
,
(69)
,
(70)
,
(71)
,
(72)
,
(73)
,
(74)
,
(75)
,
(76)
,
(77)
,
(78)
,
(79)
,
(80)
,
(81)
,
(82)
,
(83)
,
(84)
,
(85)
,
(8, 76)
,
(86)
,
(87)
,
(88)
,
(89)
,
(90)
,
(91)
,
(92, 93)
,
(94)
,
(95)
,
(96)
,
(97)
,
(98, 99)
,
(100)
,
(101)
,
(102, 103)
,
(104)
,
(105)
,
(106)
,
(8)
,
(107)
,
(108)
,
(109)
,
(76)
,
(110)
,
(111)
,
(112)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
Bernard Fox
Connectez-vous pour contacter l'auteur
- Function : Correspondent author
- PersonId : 899094
Connectez-vous pour contacter l'auteur
Lisa Butterfield
- Function : Author
- PersonId : 899092
James Allison
- Function : Author
- PersonId : 924457
Ernest Borden
- Function : Author
- PersonId : 924463
Glenn Dranoff
- Function : Author
- PersonId : 924474
Stephen F. Hodi
- Function : Author
- PersonId : 924953
Beatrix Kotlan
- Function : Author
- PersonId : 924496
Rejean Lapointe
- Function : Author
- PersonId : 924497
Michael Lotze
- Function : Author
- PersonId : 899116
Cornelius Melief
- Function : Author
- PersonId : 924503
Giorgio Parmiani
- Function : Author
- PersonId : 924513
Gerd Ritter
- Function : Author
- PersonId : 924518
Hiroshi Shiku
- Function : Author
- PersonId : 899130
Zhigang Tian
- Function : Author
- PersonId : 924527
Ena Wang
- Function : Author
- PersonId : 899091
Abstract
Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer.
Fichier principal
1479-5876-9-214.pdf (1.02 Mo)
Télécharger le fichier
1479-5876-9-214.xml (118.36 Ko)
Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other